Touyz R M, Sventek P, Larivière R, Thibault G, Fareh J, Reudelhuber T, Schiffrin E L
Medical Research Council of Canada (MRC) Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada.
Hypertension. 1996 May;27(5):1090-6. doi: 10.1161/01.hyp.27.5.1090.
We determined the effects of angiotensin II (Ang II) on cytosolic free calcium concentrations ([Ca2+]i) in the absence and presence of the selective angiotensin subtype 1 (AT1) receptor antagonist losartan or the selective AT2 antagonist PD 123319 in cultured neonatal rat atrial and ventricular cardiomyocytes. We also Ang II receptor density, affinity, and mRNA expression. [Ca2+]i was measured in single cells microphotometrically and by fluorescent digital imaging with fura 2 methodology. Receptor parameters were assessed by competitive binding studies with 125I-[Sar1,Ile8]Ang II in the presence of increasing concentrations of [Sar1,Ile8]Ang II, losartan, and PD 123319. AT1 receptor (types AT1A and AT1B) mRNA abundance was measured by reverse transcription-polymerase chain reaction. Ang II produced concentration-dependent increases in [Ca2+]i values in atrial and ventricular cells were similar but Ang II (10-9 mol/L)-induced [Ca2+]i changes were significantly greater in atrial compared with ventricular cells Ang II responses were blocked by losartan (10-7 mol/L) but not PD 123319 (10-7 mol/L). Binding studies demonstrated a single class of high-affinity. Ang II binding sites on cardiomyocyte membranes (Kd = 0.71 +/- 0.11 mumol/L). 125I-[Sar1,Ile8]Ang II was displaced by losartan but not by PD 123319. AT1 receptor mRNA was detected by reverse transcription-polymerase chain reaction in cells from atria and ventricles. In atrial cardiomyocytes, both AT1A and AT1B receptor genes were expressed, whereas in ventricular cardiomyocytes, only the AT1A receptor gene was expressed. These data demonstrate that neonatal cardiomyocytes possess Ang II receptors of the AT1 receptor subtype that are linked to [Ca2+]i signaling pathways. The different Ang II-induced [Ca2+]i responses between atrial and ventricular cells may be related to differences in the distribution of AT1 receptor subtype subvariants.
我们在培养的新生大鼠心房和心室心肌细胞中,测定了在不存在和存在选择性血管紧张素1型(AT1)受体拮抗剂氯沙坦或选择性AT2拮抗剂PD 123319的情况下,血管紧张素II(Ang II)对胞质游离钙浓度([Ca2+]i)的影响。我们还测定了Ang II受体密度、亲和力和mRNA表达。采用fura 2方法通过单细胞显微光度测定法和荧光数字成像法测量[Ca2+]i。在存在递增浓度的[Sar1,Ile8]Ang II、氯沙坦和PD 123319的情况下,通过与125I-[Sar1,Ile8]Ang II的竞争性结合研究评估受体参数。通过逆转录-聚合酶链反应测量AT1受体(AT1A和AT1B型)mRNA丰度。Ang II使心房和心室细胞中的[Ca2+]i值呈浓度依赖性增加,两者相似,但与心室细胞相比,Ang II(10-9 mol/L)诱导的心房细胞[Ca2+]i变化显著更大。Ang II反应被氯沙坦(10-7 mol/L)阻断,但未被PD 123319(10-7 mol/L)阻断。结合研究证明心肌细胞膜上存在一类高亲和力的Ang II结合位点(Kd = 0.71 +/- 0.11 μmol/L)。125I-[Sar1,Ile8]Ang II被氯沙坦取代,但未被PD 123319取代。通过逆转录-聚合酶链反应在心房和心室细胞中检测到AT1受体mRNA。在心房心肌细胞中,AT1A和AT1B受体基因均有表达,而在心室心肌细胞中,仅表达AT1A受体基因。这些数据表明,新生心肌细胞拥有与[Ca2+]i信号通路相关的AT1受体亚型的Ang II受体。心房和心室细胞之间不同的Ang II诱导的[Ca2+]i反应可能与AT1受体亚型变体的分布差异有关。